Your browser doesn't support javascript.
loading
SARS-CoV-2 infectious virus, viral RNA in nasopharyngeal swabs, and serostatus of symptomatic COVID-19 outpatients in the United States
Katie R. Mollan; Joseph J. Eron; Taylor J. Krajewski; Wendy Painter; Elizabeth R. Duke; Caryn G. Morse; Erin A. Goecker; Lakshmanane Premkumar; Cameron R. Wolfe; Laura J. Szewczyk; Paul L. Alabanza; Amy James Loftis; Emily J. Degli-Angeli; Ariane J. Brown; Joan A. Dragavon; John J. Won; Jessica Keys; Michael G. Hudgens; Lei Fang; David A. Wohl; Myron S. Cohen; Ralph S. Baric; Robert W. Coombs; Timothy P. Sheahan; William A. Fischer II.
Afiliação
  • Katie R. Mollan; University of North Carolina at Chapel Hill
  • Joseph J. Eron; University of North Carolina at Chapel Hill
  • Taylor J. Krajewski; University of North Carolina at Chapel Hill
  • Wendy Painter; Ridgeback Biotherapeutics LP, Miami, Florida 33133
  • Elizabeth R. Duke; Fred Hutchinson Cancer Research Center
  • Caryn G. Morse; Wake Forest School of Medicine
  • Erin A. Goecker; Department of Laboratory Medicine and Pathology, University of Washington
  • Lakshmanane Premkumar; University of North Carolina at Chapel Hill
  • Cameron R. Wolfe; Duke University Medical Center
  • Laura J. Szewczyk; Ridgeback Biotherapeutics LP, Miami, Florida 33133
  • Paul L. Alabanza; University of North Carolina at Chapel Hill
  • Amy James Loftis; University of North Carolina at Chapel Hill
  • Emily J. Degli-Angeli; Department of Laboratory Medicine and Pathology, University of Washington
  • Ariane J. Brown; University of North Carolina at Chapel Hill
  • Joan A. Dragavon; Department of Laboratory Medicine and Pathology, University of Washington
  • John J. Won; University of North Carolina at Chapel Hill
  • Jessica Keys; University of North Carolina at Chapel Hill
  • Michael G. Hudgens; University of North Carolina at Chapel Hill
  • Lei Fang; Pharstat Inc., Raleigh, NC
  • David A. Wohl; University of North Carolina at Chapel Hill
  • Myron S. Cohen; University of North Carolina at Chapel Hill
  • Ralph S. Baric; University of North Carolina at Chapel Hill
  • Robert W. Coombs; Department of Laboratory Medicine and Pathology, University of Washington
  • Timothy P. Sheahan; University of North Carolina at Chapel Hill
  • William A. Fischer II; University of North Carolina at Chapel Hill
Preprint em Inglês | medRxiv | ID: ppmedrxiv-21258011
ABSTRACT
BackgroundWhile SARS-CoV-2 infectious virus isolation in outpatients with COVID-19 has been associated with viral RNA levels and symptom duration, little is known about the host, disease and viral determinants of infectious virus detection. MethodsCOVID-19 adult outpatients were enrolled within 7 days of symptom onset. Clinical symptoms were recorded via patient diary. Nasopharyngeal swabs were collected to quantitate SARS-CoV-2 RNA by reverse transcriptase polymerase chain reaction and for infectious virus isolation in Vero E6-cells. SARS-CoV-2 antibodies were measured in serum using a validated ELISA assay. ResultsAmong 204 participants with mild-to-moderate symptomatic COVID19, the median nasopharyngeal viral RNA was 6.5 (IQR 4.7-7.6 log10 copies/mL), and 26% had detectable SARS-CoV-2 antibodies (IgA, IgM, IgG, and/or total Ig) at baseline. Infectious virus was recovered in 7% of participants with SARS-CoV-2 antibodies compared to 58% of participants without antibodies (probability ratio (PR)=0.12, 95% CI 0.04, 0.36; p=0.00016). Infectious virus isolation was also associated with higher levels of viral RNA (mean RNA difference +2.6 log10, 95% CI 2.2, 3.0; p<0.0001) and fewer days since symptom onset (PR=0.79, 95% CI 0.71, 0.88 per day; p<0.0001). ConclusionsThe presence of SARS-CoV-2 antibodies is strongly associated with clearance of infectious virus isolation. Seropositivity and viral RNA levels are likely more reliable markers of infectious virus clearance than subjective measure of COVID-19 symptom duration. Virus-targeted treatment and prevention strategies should be administered as early as possible and ideally before seroconversion. ClinicalTrials.gov IdentifierNCT04405570 Key Points (Summary)Among COVID-19 outpatients within 7 days of symptom onset, the presence of SARS-CoV-2-specific antibodies was strongly associated with clearance of infectious virus. Seropositivity appears to be more reliable marker of infectious virus clearance than subjective measure of COVID-19 symptoms.
Licença
cc_by_nc_nd
Texto completo: Disponível Coleções: Preprints Base de dados: medRxiv Tipo de estudo: Estudo prognóstico Idioma: Inglês Ano de publicação: 2021 Tipo de documento: Preprint
Texto completo: Disponível Coleções: Preprints Base de dados: medRxiv Tipo de estudo: Estudo prognóstico Idioma: Inglês Ano de publicação: 2021 Tipo de documento: Preprint
...